Investment Case

  • Sparta offer

    Sparta AG published the offer document for the takeover bid to the shareholders of 4basebio AG for the acquisition of the no-par value registered shares of 4basebio AG (ISIN DE000A2YN801…

    View
  • Spin-off Project

    4basebio AG announces process for spin-off and separate stock market listing for its DNA business Following a strategic review, 4basebio AG announced on 17 August 2020 its intention to commence…

    View
  • Overview

    – 4basebio: a manufacturer of pharmaceutical grade DNA
    – New manufacturing processes
    – Pursueing vertical integration for gene therapy and DNA vaccines

    View
  • Market Opportunities

    An increasing demand for pharmaceutical grade DNA
    4basebio designs a new synthetic production:
    – Highly effective
    – Scalable
    – Fast
    – Safer

    View
  • 4basebio’s Technology

    – Fully synthetic, scalable and cell-free manufacturing process
    – High yield
    – Proprietary enzyme technologies
    – Wide range of applications

    View
  • Analyst Reports

    25 August 2020: First Berlin, Analyst Christian Orquera – Update note after H1 2020 financial results 15 July 2020: First Berlin, Analyst Christian Orquera –  “AIMING TO DISRUPT THE DNA…

    View
  • FAQs

    What does 4basebio do? 4basebio is developing a production method for next generation synthetic DNA (hairpin-DNA, hp-DNA). Our products will be the active ingredient in future gene therapies and gene…

    View